Polycyclo Ring System Patents (Class 514/680)
  • Patent number: 10263280
    Abstract: The problem addressed was that of providing novel polymers which are preparable with a low level of complexity, with the possibility of controlled influence on the physicochemical properties thereof within wide limits in the course of synthesis, and which are usable as active media in electrical charge storage elements for high storage capacity, long lifetime and stable charging/discharging plateaus. 9,10-Bis(1,3-dithiol-2-ylidene)-9,10-dihydroanthracene polymers consisting of an oligomeric or polymeric compound of the general formula I have been found.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: April 16, 2019
    Assignee: Evonik Degussa Gmbh
    Inventors: Bernhard Haeupler, Ulrich Schubert, Andreas Wild
  • Patent number: 9795570
    Abstract: Methods and materials that can be used to regulate macrophage activation are described. Methods can utilize emodin to bi-directionally modulate macrophage activation and return macrophage phenotype to a homeostatic center (e.g., between M1 and M2 phenotypes) in various environmental settings. Methods can target multiple pathologies within a same individual. Methods can be utilized to inhibit macrophage phenotype activation and affect downstream response to phenotype inducing stimulus, thereby altering macrophage memory.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: October 24, 2017
    Assignee: University of South Carolina
    Inventor: Daping Fan
  • Patent number: 9586885
    Abstract: Described are compounds of the structural formula (I): Also provided are pharmacologically acceptable isomers and salts of the compound of (I). The compounds are useful in the treatment of inflammatory bowel disease.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: March 7, 2017
    Assignee: Venantius Limited
    Inventors: Neil Frankish, Helen Sheridan
  • Publication number: 20150148428
    Abstract: Disclosed herein are a nanopreparation having a micelle structure for diagnosis or treatment of cancer diseases, and a method of preparing the same, and more particularly, a nanopreparation having a micelle structure available for diagonosis or treatment of cancer diseases and a method for preparing the same, wherein the nanopreparation is prepared by encapsulating a photosensitizer by forming micelle with polymeric lipid DSPE-mPEG. The nanopreparation having the micelle structure according to the present invention has a size of 12 nm or less by encapsulating hypericin, which is a photosensitizer, by forming micelle with polymeric lipid DSPE-mPEG having a molecular weight of 1500 to 2500. Resultingly, the nanopreparation easily overcomes a blood-tumor barrier (BTB) and an interstitial fluid pressure and has light induced cytotoxicity efficiency that is about more than 2.5 times higher than that of the case where hypericin is used alone.
    Type: Application
    Filed: June 26, 2014
    Publication date: May 28, 2015
    Inventors: Chulhee Choi, Kyuha Chong, Jiho Park
  • Patent number: 9000222
    Abstract: The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, a wound (the compounds assist with wound healing), acne, rheumatoid arthritis, psoriasis, rosacea, and alopecia; Kennedy's disease (spinal and bulbar muscular atrophy, or SBMA), polyglutamine-mediated motor neuron degeneration; cancers such as prostate cancer, bladder cancer, breast cancer, ovarian cancer, hepatocellular (liver) cancer, and pancreatic cancer; and other medical conditions described herein. Treatment of such medical conditions includes administering to an individual suffering from a medical condition describe herein, a therapeutically effective amount of any of the disclosed compounds, their derivatives, or pharmaceutical compositions thereof.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: April 7, 2015
    Assignee: Androscience Corporation
    Inventors: Charles Shih, Qian Shi, Hui-Kang Wang
  • Publication number: 20150072012
    Abstract: A highly bioavailable, water soluble, sustained release nanoformulation comprising a hydrophobic plant derived compound(s) in an emulsifier phase, and aqueous phase. The formulation provides sustained release of the hydrophobic plant derived compound(s) over a 24 hr time period. A process for preparation of the water soluble nanoformulation is described.
    Type: Application
    Filed: November 13, 2014
    Publication date: March 12, 2015
    Inventors: Ravichandran SRIPATHY, Venkata Narasimha Siva Rama Raju MANDAPATI, Gopaal AJAY, Nirvanashetty SOMASHEKARA, Ramchand Nanappan CHANIYILPARAMPU, Rama Raju GOKARAJU, Ganga Raju GOKARAJU, Kiran BHUPATHIRAJU, Dwarakanath ANJANA
  • Patent number: 8951992
    Abstract: The present invention is directed to methods and compounds for inhibiting bacterial growth and treating a bacterial infection in a subject. These methods involve providing an inhibitor of intrabacterial pH homeostasis, including inhibitors of the Mycobacterium tuberculosis Rv3671c gene encoded membrane protease. Methods for identifying novel compounds that disrupt intrabacterial pH homeostasis and their use for inhibiting bacterial growth and treating a bacterial infection in a subject are also disclosed.
    Type: Grant
    Filed: July 20, 2009
    Date of Patent: February 10, 2015
    Assignee: Cornell University
    Inventors: Carl Nathan, Sabine Ehrt, Omar Vandal, Crystal Darby
  • Publication number: 20150018301
    Abstract: Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration were identified. The presently disclosed subject matter establishes that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for treating Parkinson's disease.
    Type: Application
    Filed: November 8, 2010
    Publication date: January 15, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Byoung Dae Lee, Ted M. Dawson, Valina L. Dawson, Andrew B. West, Howard Federoff
  • Publication number: 20140356455
    Abstract: Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided.
    Type: Application
    Filed: December 6, 2013
    Publication date: December 4, 2014
    Applicants: The Board of Trustees of the Leland Stanford Junior University, Parkinson's Institute
    Inventors: Renee Ann Reijo Pera, J. William Langston, Birgitt Schule, Theodore D. Palmer, Blake Byers, Ha Nam Nguyen, James Anthony Byrne, Branden John Cord
  • Patent number: 8889197
    Abstract: Combinations, compositions and methods of use for modulating plant pathogen infection using plant extracts containing anthraquinone derivatives which induce resistance to plant phytopathogens and an antimicrobial agent, a biological control agent and/or a surfactant having fungicidal activity.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: November 18, 2014
    Assignee: Marrone Bio Innovations, Inc.
    Inventors: Hai Su, Marja Koivunen, Pamela G Marrone
  • Publication number: 20140323420
    Abstract: Described herein are compositions and methods for treating or preventing a sexually transmitted infection in a subject
    Type: Application
    Filed: November 8, 2012
    Publication date: October 30, 2014
    Inventors: Stephen Dewhurst, David Easterhoff, Brad Nilsson, John Dimaio, Alan Smrcka, Jerry Yang, Christina Capule
  • Patent number: 8846732
    Abstract: Biogenic sulfide production is synergistically inhibited by treating sulfate-reducing bacteria (SRB) with a biocide and a metabolic inhibitor. The biocide directly kills a first portion of the SRB. The metabolic inhibitor inhibits sulfate-reducing growth of a second portion of the SRB without directly killing the second portion of the SRB. The treatment of SRB with both a biocide and a metabolic inhibitor provides effective biogenic sulfide inhibition at significantly lower concentrations than would be required if the biocide or metabolic inhibitor was used alone.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: September 30, 2014
    Assignees: ConocoPhillips Company, University Technologies International, Inc.
    Inventors: Gary E. Jenneman, Anne Greene, Gerrit Voordouw
  • Publication number: 20140170229
    Abstract: Biodegradable polymeric nanoparticles comprising an inner core formed of a photodynamic agent capable of being activated to generate cytotoxic singlet oxygen are prepared. These nanoparticles have anti-cell proliferation activity and are useful in treating both cancerous and non-cancerous conditions including actinic keratosis, psoriasis and acne vulgaris. Preferably, the photodynamic agent is a hypocrellin B derivative while the polymeric nanoparticle comprises polyglycolic acid, polylactic acid or poly(lactide-co-glycolide). Hypocrellin-comprising nanoparticles are demonstrated to be activated by light or hydrogen peroxide.
    Type: Application
    Filed: August 11, 2011
    Publication date: June 19, 2014
    Applicant: Quest Pharmatech Inc.
    Inventors: Azita Haddadi, Ragupathy Madiyalakan, Thomas Woo
  • Patent number: 8754242
    Abstract: Compounds of formula (I) wherein the substituents are as defined in claim 1, are suitable for use as herbicides.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: June 17, 2014
    Assignees: Syngenta Crop Protection LLC, Syngenta Limited
    Inventors: Melloney Tyte, Christopher John Matthews, Gavin John Hall, William Guy Whittingham, Jeffrey Steven Wailes, James Nicholas Scutt, Stephane André Marie Jeanmart, Russell Colin Viner
  • Publication number: 20140154180
    Abstract: This invention relates, e.g., to a method for designing or selecting on a computer a candidate small molecule amyloid binder or inhibitor, comprising: a) docking test compounds to the binding site or binding surface determined from the three-dimensional structure of a co-crystal of a protofilament of an amyloid protein bound to a small molecule which is known to bind to the amyloid protein, and (b) selecting test compounds which exhibit an energy below that of the small molecule used to form the co-crystal made in a), as candidate amyloid binders.
    Type: Application
    Filed: July 16, 2012
    Publication date: June 5, 2014
    Applicant: The Regents of the University of California
    Inventors: David S. Eisenberg, Lin Jiang, Meytal Landau, Cong Liu
  • Publication number: 20140135359
    Abstract: The present invention provides a computer-assisted method of generating a protonophore requiring the use of a computer including a processor. The method includes: designing the protonophore, calculating, using the processor, an estimated protonophoric activity; producing the protonophore if the estimated protonophoric activity corresponds to an U50 of about 20 ?M or less; and determining the uncoupling activity of the protonophore. The present invention also provides novel protonophores that meet the above requirement and their methods of use.
    Type: Application
    Filed: November 12, 2012
    Publication date: May 15, 2014
    Inventor: Louis C. Martineau
  • Patent number: 8710272
    Abstract: The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, a wound (the compounds assist with wound healing), acne, rheumatoid arthritis, psoriasis, rosacea, and alopecia; Kennedy's disease (spinal and bulbar muscular atrophy, or SBMA), polyglutamine-mediated motor neuron degeneration; cancers such as prostate cancer, bladder cancer, breast cancer, ovarian cancer, hepatocellular (liver) cancer, and pancreatic cancer; and other medical conditions described herein. Treatment of such medical conditions includes administering to an individual suffering from a medical condition describe herein, a therapeutically effective amount of any of the disclosed compounds, their derivatives, or pharmaceutical compositions thereof.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: April 29, 2014
    Assignee: Androscience Corporation
    Inventors: Charles C. Y. Shih, Qian Shi, Hui-Kang Wang, Ching-Yuan Su
  • Publication number: 20130288989
    Abstract: Use of chemical ingredients in Cynomorium as phytoestrogen is provided by the present invention. Particularly, use of Cynomorium, extracts of Cynomorium, or at least one ingredient chosen from chrysophanol, emodin, catechin, (?)-epicatechin-3-O-gallate, naringenin-4?-O-glucopyranoside, and phlorizin, in manufacturing medicaments for treating and/or preventing diseases related to insufficient of estrogen secretion in mammal (for example, human), or use in manufacturing medicaments used as phytoestrogens is provided by the present invention. The extracts of Cynomorium, compositions containing extracts of Cynomorium or active ingredients thereof, and methods of treating and/or preventing diseases related to insufficient of estrogen secretion are also provided by the present invention.
    Type: Application
    Filed: October 14, 2010
    Publication date: October 31, 2013
    Applicant: TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
    Inventor: Xiumei Gao
  • Patent number: 8552055
    Abstract: The present invention refers to tricyclic diterpenes and their derivatives of the formulae (I) and (II), wherein R1 is hydrogen or C1-6-alkyl; R2 is hydroxy, C3-5-acyloxy, hydroxymethyl, 1,3-dihydroxypropyl or C1-6-alkyl; R3 and R4 independently from each other are hydrogen, hydroxy, hydroxymethyl, C1-5-acyloxy or C1-6-alkoxy; R5 is C1-6-alkyl, hydroxymethyl carboxy or methoxycarbonyl; R9 is hydrogen, hydroxymethyl, methoxy, oxo or C1-5-acyloxy; R10 is hydrogen, or R5 and R9 taken together are —CH2—O— or —O—CH2—; or R5 and R10 taken together are —CO—O—, —O—CO—, —CH2—O— or —O—CH2—; R6 is hydrogen, or R5 and R6 together form a bond; R7 and R8 independently from each other are C1-6-alkyl, carboxy, x-hydroxy-Cx-alkyl (with x being an integer from 1 to 6), or C1-6-alkoxycarbonyl with the proviso that at least one of R7 and R8 is C1-6-alkyl; R11 and R12 are both hydrogen or R11 and R12 together are oxo, with the further proviso for formula (I) that if R2 is hydroxy R1 is C1-6-alkyl, for use as medicaments for the t
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: October 8, 2013
    Assignee: DSM IP Assets B.V.
    Inventors: Antoine De Saizieu, Ann Fowler, Regina Goralczyk, Claus Kilpert, Goede Schueler, Christof Wehrli
  • Publication number: 20130251647
    Abstract: The invention relates to new types of modulators of the cold menthol receptor TRPM8, to methods of modulating the TRPM8 receptor using these modulators; and in particular the use of the modulators for inducing a sensation of coldness; and also the articles and compositions produced using these modulators.
    Type: Application
    Filed: September 20, 2012
    Publication date: September 26, 2013
    Applicant: BASF SE
    Inventors: Thomas Subkowski, Claus Bollschweiler, Jens Wittenberg, Wolfgang Siegel, Ralf Pelzer
  • Publication number: 20130245070
    Abstract: The present invention relates to a method for enhancing arginase activity in a damaged or injured cell. In other aspects, the invention provides a method for treating a disorder that can be treated by enhancing arginase activity in a human in need thereof, the method comprising administering to the human an effective amount of a compound that enhances arginase activity. Such disorders include ischemia, hypoxia, neurodegenerative disease or condition, stroke or trauma of the nervous system. In yet another aspect, the invention provides methods for promoting regeneration of a neural cell in a human in need thereof.
    Type: Application
    Filed: March 9, 2012
    Publication date: September 19, 2013
    Applicant: THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK
    Inventors: Rajiv R. Ratan, Marie T. Filbin
  • Publication number: 20130225675
    Abstract: Apparatus and methods to prevent the proliferation of undesired life forms in a subterranean formation, comprising forming a fluid comprising an inhibitor; and introducing the inhibitor to a surface in the formation. Apparatus and methods to prevent the proliferation of undesired life forms along a surface of tubular or equipment for use in the oil field services industry, comprising forming a coating comprising an inhibitor; and introducing the coating to a surface of the tubular or equipment. Apparatus and methods to prevent the proliferation of undesired life forms along a surface of tubular or equipment for use in the oil field services industry, comprising forming a material comprising an inhibitor; and embedding the material into a surface of the tubular or equipment.
    Type: Application
    Filed: June 29, 2011
    Publication date: August 29, 2013
    Applicant: SCHLUMBERGER TECHNOLOGY CORPORATION
    Inventors: Gregory Kubala, Iain Cooper, Shawn McCleskey Rimassa, Robert Seth Hartshorne
  • Publication number: 20130225517
    Abstract: The invention provides compounds of formula I: or salts thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I and therapeutic methods for treating cancer.
    Type: Application
    Filed: February 22, 2013
    Publication date: August 29, 2013
    Applicant: University of Iowa Research Foundation
    Inventor: University of Iowa Research Foundation
  • Patent number: 8519007
    Abstract: The present invention discloses certain diterpenes that can be used to inhibit androgen receptor activity, induce apoptosis and block cell cycle progression of androgen receptor-dependent cells. Androgen receptor has been associated with various diseases such as prostate cancer, androgeneic alopecia, breast cancer, acne etc. Accordingly, the present invention further discloses methods of treating androgen receptor-associated diseases by administering the disclosed diterpenes.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: August 27, 2013
    Assignee: Academia Sinica
    Inventors: Pei-Wen Hsiao, Feng-Min Lin, Sheng-Yang Wang
  • Publication number: 20130217674
    Abstract: Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and A are as defined herein are disclosed. Such compounds have enhanced water solubility and have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Enantioselective methods for preparation of compounds of structure (I), compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluents and methods of SHIP1 modulation by administration of such compounds to an animal in need thereof are also disclosed.
    Type: Application
    Filed: August 22, 2011
    Publication date: August 22, 2013
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Xiaoxia Wang, Labros George Meimetis, Matthew Bruce Nodwell, Raymond Andersen
  • Publication number: 20130211371
    Abstract: A liquid or ointment formulation for the treatment of a skin condition associated with leukocyte accumulation in the skin includes a therapeutic compound selected to reduce leukocyte accumulation in the skin and an aqueous solution of an organic solvent. The organic solvent increases skin permeability. A method of treating a skin condition associated with leukocyte accumulation in the skin includes the steps of applying topically a liquid formulation of a photosensitizer to a skin lesion of a patient afflicted with the skin condition and exposing the skin lesion to a light source.
    Type: Application
    Filed: April 20, 2011
    Publication date: August 15, 2013
    Applicant: Hy Biopharma, Inc.
    Inventors: Alfonso J. Tobia, Bernard E. Cabana, Alain H. Rook
  • Publication number: 20130210775
    Abstract: Provided is an agent for reducing odors of pyrazine derivatives based on an olfactory receptor antagonism. The agent for reducing odors of pyrazine derivatives includes at least one antagonist of olfactory receptor OR5K1 as an active ingredient.
    Type: Application
    Filed: December 4, 2012
    Publication date: August 15, 2013
    Applicant: Kao Corporation
    Inventor: Kao Corporation
  • Publication number: 20130209534
    Abstract: A substrate of polymeric material for wound care contains at least one oleous antimicrobial and/or helping tissue regeneration substance that is selected from Hyperforin, Adhyperforin, 1-3 Diapigenin, 11-8 Diapigenin, Rutin, Quercetin, Hypericin, Azadirachtin ?-?, Nimbin, Nimbidin, Salanin, Gallic Acid, Gedunin and combinations thereof.
    Type: Application
    Filed: June 4, 2012
    Publication date: August 15, 2013
    Applicant: MOSES S.R.L.
    Inventors: Chiara GUALANDI, Maria Letizia FOCARETE, Andrea ZUCCHELLI, Maria Letizia IABICHELLA
  • Publication number: 20130196953
    Abstract: The invention relates to tetracycline products produced by genetically engineered cells, and to therapeutic methods using such tetracyclines. The present invention is based on the cloning and heterologous expression of genes encoding the chelocardin biosynthetic pathway.
    Type: Application
    Filed: January 28, 2013
    Publication date: August 1, 2013
    Applicant: UNIVERZA V LJUBLJANI
    Inventor: UNIVERZA V LJUBLJANI
  • Patent number: 8466202
    Abstract: This invention relates compositions containing compounds of formula (I) below: Each of R1, R2, R3, R4, R5, R6, R7, and R8 is defined in the specification.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: June 18, 2013
    Assignee: Sunten Phytotech Co., Ltd.
    Inventors: Du-Shieng Chien, Yi-Wen Chu, Wu-Chang Chuang, Ming-Chung Lee
  • Publication number: 20130090355
    Abstract: The present invention provides methods of preventing or inhibiting tumor metastasis in a subject by administering a therapeutically effective amount of (1) a compound from a group of enumerated compounds, or a pharmaceutically acceptable salt thereof; (2) an agent that covalently modifies at least one cysteine residue of S100A4 protein; or (3) an agent that inhibits the interaction between S100A4 and myosin-IIA.
    Type: Application
    Filed: April 28, 2011
    Publication date: April 11, 2013
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
    Inventor: Anne R. Bresnick
  • Publication number: 20130065850
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.
    Type: Application
    Filed: April 3, 2012
    Publication date: March 14, 2013
    Applicant: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Josh MUNGER, Bryson BENNETT, Thomas SHENK, Joshua RABINOWITZ
  • Publication number: 20130035284
    Abstract: The present invention concerns methods and compositions involving small molecule inhibitors for the treatment or prophylaxis of flavivirus infection, such as dengue virus and West Nile virus.
    Type: Application
    Filed: March 5, 2012
    Publication date: February 7, 2013
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Stanley J. Watowich, Suzanne M. Tomlinson, Scott Gilbertson
  • Publication number: 20120322717
    Abstract: The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In one aspect, the virtual screening process could be carried out where a permutational library of small peptides is substituted for the small organic molecules. The inventive methods may be used to empirically test for effects on Wnt activity and may also be applied to any pair of proteins involved in protein-protein interactions.
    Type: Application
    Filed: May 22, 2009
    Publication date: December 20, 2012
    Inventors: Dakai Liu, Xiaofeng Li, Richard Jin, Yuaxin Liang, Wei Cheng, Riddhi Bhattacharyya, Guangrong Zhang
  • Publication number: 20120322757
    Abstract: A composition and process for generating an anthraquinone rich aloe product from aloe leaves comprising the steps of: removing one or more rind parts from the aloe leaves comprising a top rind, a bottom rind, or both by filleting the aloe leaves on a filleting table into a mucilage layer below the rind parts of the aloe leaves to remove the top rind, the bottom rind, or both from an internal fillet or a gel layer; and separating the internal fillet or the gel layer from the rind parts; removing a mucilage layer attached to the one or more rind parts by scraping, heat-treating the rind parts and the extracted mucilage; and adding one or more preservatives to the heat-treated mucilage after cooling, wherein the extracted and heat-treated mucilage comprises the anthaquinone rich aloe product.
    Type: Application
    Filed: June 14, 2012
    Publication date: December 20, 2012
    Applicant: COATS ALOE INTERNATIONAL, INC.
    Inventors: Billy C. Coats, Ivan E. Danhof
  • Patent number: 8324262
    Abstract: The present invention features compounds, pharmaceutical compositions, and methods for treating trauma, ischemia, stroke, degenerative diseases associated with cellular necrosis, and other conditions. Screening assays for identifying compounds useful for treating these conditions are also described.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: December 4, 2012
    Assignees: The Brigham and Women's Hospital, Inc., President and Fellows of Harvard College
    Inventors: Junying Yuan, Alexei Degterev, Junichi Hitomi, Gregory D. Cuny, Prakash Jagtap
  • Publication number: 20120283267
    Abstract: Methods of treating exposure to Giardia lamblia and/or giardiasis and methods of antagonizing Giardia lamblia attachment to the intestinal wall of a subject are described herein.
    Type: Application
    Filed: December 2, 2010
    Publication date: November 8, 2012
    Applicant: GEORGETOWN UNIVERSITY
    Inventors: Heidi G. Elmendorf, Colleen D. Walls, Christian Wolf
  • Publication number: 20120238549
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: March 15, 2012
    Publication date: September 20, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Kevin P. Cusack, Thomas D. Gordon, David C. Ihle, Martin E. Hayes, Eric C. Breinlinger, Anna M. Ericsson, Bin Li, Lei Wang, Gloria Y. Martinez, Andrew Burchat, Adrian D. Hobson, Kelly D. Mullen, Michael Friedman, Michael J. Morytko
  • Publication number: 20120208750
    Abstract: Described are methods of improving insulin sensitivity, and treating fatty liver disease (including non-alcoholic steatohepatitis (NASH)), by administering specific inhibitors of PKC delta.
    Type: Application
    Filed: September 29, 2010
    Publication date: August 16, 2012
    Applicant: JOSLIN DIABETES CENTER, INC.
    Inventors: C. Ronald Kahn, Olivier Bezy
  • Publication number: 20120202738
    Abstract: There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent.
    Type: Application
    Filed: October 22, 2010
    Publication date: August 9, 2012
    Inventor: Thomas Julius Borody
  • Patent number: 8236852
    Abstract: The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, acne, alopecia, hirsutism, a wound, prostate cancer, bladder cancer, liver cancer, breast cancer and Kennedy's disease.
    Type: Grant
    Filed: January 8, 2008
    Date of Patent: August 7, 2012
    Assignee: Androscience Corporation
    Inventors: Charles C. Y. Shih, Qian Shi, Hui-Kang Wang, Ching-Yuan Su
  • Publication number: 20120196751
    Abstract: Provided is a formulation comprising (a) a preparation comprising one or more anthraquinone derivatives having activity against plant pests and (b) a lignin. Also provided is a method for obtaining the formulation and for using the formulation to modulate phytopathogenic, fungal and/or bacterial infection and/or plant pest infestation.
    Type: Application
    Filed: February 2, 2012
    Publication date: August 2, 2012
    Applicant: MARRONE BIO INNOVATIONS, INC.
    Inventors: James Namnath, Hai Su
  • Patent number: 8202905
    Abstract: The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, acne, alopecia, hirsutism, a wound, prostate cancer, bladder cancer, liver cancer, breast cancer and Kennedy's disease.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: June 19, 2012
    Assignee: Androscience Corporation
    Inventors: Charles C. Y. Shih, Qian Shi, Hui-Kang Wang, Ching-Yuan Su
  • Publication number: 20120129927
    Abstract: The invention relates to two novel substances, namely (1R,2S,3S,4R)-3-acetoxy-1,2,4,5-tetrahydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydroanthracene-9,10-dione (3-O-acetyl altersolanol M) and 8-(4,5,6-trihydroxy-7-methyl-2-methoxy-9,10-dioxo-9H,10H-anthracen-1-yl)-(1S,2S,3R,4S)-1,2,3,4,5-pentahydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydro-9H,10H-anthracene-9,10-dione (the atropisomers alterporriol I and J) to their use as anti-infectives and as anti-cancer agents, as well as to methods of producing the same.
    Type: Application
    Filed: May 31, 2010
    Publication date: May 24, 2012
    Applicant: SEALIFE PHARMA GMBH
    Inventors: Alexander Pretsch, Peter Proksch, Abdessamad Debbab
  • Publication number: 20120129949
    Abstract: The present invention relates to the use of the following anthracene derivatives as anti-infectives, preferably against multiply drug resistant pathogens: (2R,3S,10R)-2,3,5,10-tetrahydroxy-6-methoxy-3-methyl-1,2,3,4,4a,9a-hexahydro-9H,10H-anthracen-9-one (tetrahydroaltersolanol B), (1R,2R,3R,4aS,9aR,10R)-1,2,3,5,10-pentahydroxy-7-methoxy-2-methyl-1,2,3,4,4a,9a-hexahydro-9H,10H-anthracen-9-one (altersolanol K), (2R,3R,4R,4aS,9aS,10R)-2,3,4,8,10-pentahydroxy-6-methoxy-3-methyl-1,2,3,4,4a,9a-hexahydro-9H,10H-anthracen-9-one (altersolanol L), 8-(1,7-dihydroxy-6-methyl-3-methoxy-9,10-dioxo-9H,10H-anthracen-2-yl)-(1S,2S,3R,4S)-1,2,3,4,5-pentahydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydro-9H,10H-anthracen-9,10-dione (atropisomers alterporriol G and H); as well as (2R,3S,4aS,9aS,10R)-2,3,5,8,10-pentahydroxy-6-methoxy-3-methyl-1,2,3,4,4a,9a-hexahydro-9H,10H-anthracen-9-one (8-hydroxytetrahydroaltersolanol B).
    Type: Application
    Filed: May 31, 2010
    Publication date: May 24, 2012
    Applicant: SEALIFE PHARMA GMBH
    Inventors: Alexander Pretsch, Peter Proksch, Abdessamad Debbab
  • Publication number: 20120115862
    Abstract: The present invention relates to compounds of the formula I wherein R1, R2, R3, R4, X and Y have the meanings given in the description. The compounds have an action which is immunomodulating and inhibits or regulates the release of IL-1? and/or TNF-?. They can therefore be used for treatment of diseases connected with a disturbance in the immune system.
    Type: Application
    Filed: October 9, 2009
    Publication date: May 10, 2012
    Inventors: Stefan Laufer, Wolfgang Albrecht
  • Publication number: 20120115728
    Abstract: Compositions for modulating plant growth, seed germination and soil borne diseases comprising anthraquinone derivatives are disclosed.
    Type: Application
    Filed: November 3, 2011
    Publication date: May 10, 2012
    Applicant: Marrone Bio Innovations
    Inventors: Hai Su, Pamela Marrone, Jason Lee Osborne
  • Publication number: 20120059067
    Abstract: A composition may include a pharmaceutical carrier and an amount, therapeutically effective for the treatment of a retinal disease, of CLT-005 (1-acetyl-5-hydroxyanthracene-9,10-dione), wherein the retinal disease is characterized by at least one of inflammation, angiogenesis, or neovascularization, and wherein the composition is prepared for administration topically. The composition may be administered topically to a subject's eye.
    Type: Application
    Filed: November 11, 2011
    Publication date: March 8, 2012
    Applicant: CHARLESSON, LLC
    Inventor: Rafal A. Farjo
  • Publication number: 20120053154
    Abstract: Compositions and methods for inhibiting sulfide biogeneration from biofilms are described, as well as methods for preparing the compositions. The compositions comprise anthrahydroquinone and a biocide. The compositions may also include anthraquinone.
    Type: Application
    Filed: August 24, 2010
    Publication date: March 1, 2012
    Applicant: Arkion Life Sciences
    Inventors: Edward D. Burger, Celia D. Youngren
  • Patent number: RE44704
    Abstract: The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at least one immunoconjugate and at least one chemotherapeutic agent and to methods of treating cancer using at least one immunoconjugate and at least one chemotherapeutic agent. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one chemotherapeutic agent and at least one immunoconjugate.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: January 14, 2014
    Assignee: Immunogen Inc.
    Inventors: Ravi V. J. Chari, Walter A. Blättler